Cytodyn Inc (CYDY)

[kgromax]

You cant compare both. CD12 is for severe and critical patients. Your study automatically qualifies for critical only (read Cytodyn’s CD12 trial criteria).

Additionally, Cytodyn excludes the most critical patients (high respiratory risk and/or vasopressors for >48 hours)...yes Cytodyn excludes the high risk criticals. While they are included in the study you have quoted.

So you are comparing a much milder (on average) population (Cytodyn’s CD12) with the very last step before the cemetery. If you do that then I could compare against severe-only studies with a 5% mortality. That would be equally meaningless.

I was very preoccupied with these benchmark questions a couple months ago. Invested quite a lot of men days reviewing in depth 50+ papers worldwide (both studies and meta analysis), both US and non-US, that covered exactly the severe to critical spectrum. No milds, no moderates, no severes-only, no criticals-only. They all had mortalities between 12-24% with an average (across studies) of 18%. US-only average was also 18%.